Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares. This total includes 150,956 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028, highlighting a multi-year, equity-based incentive structure aligned with her leadership role.
TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.
The RSUs vest in three equal-time tranches: 63,758 on July 1, 2026, 63,758 on July 1, 2027 and 63,764 on July 1, 2028.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.
The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.
Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti. He reports direct ownership of 144,608 American Depositary Shares. This total includes 53,850 restricted stock units, each representing one ADS, vesting on July 1, 2026, July 1, 2027, and July 1, 2028 in scheduled installments.
Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company. He directly holds 27,865 Ordinary Shares. The filing also notes 8,400 restricted stock units (RSUs), each representing a right to receive one Ordinary Share as they vest.
The RSUs vest on June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares). Separate Tax Obligation Awards are described as economically equivalent to Ordinary Shares but payable in cash primarily to cover tax obligations at future vesting.
Takeda Pharmaceutical director Emiko Higashi filed an initial ownership report showing equity and award holdings in the company. The filing lists 7,600 American Depositary Shares and 17,800 Ordinary Shares held directly, plus restricted stock units and tax-related awards tied to future vesting.
Footnotes explain that 12,800 restricted stock units each convert into one Ordinary Share, then into American Depositary Shares, vesting on June 1, 2026, 2027, 2028 and upon conclusion of board service. Separate Tax Obligation Awards are each economically equivalent to one Ordinary Share and will be settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD executive Asuka Miyabashira, President of the Japan Pharma Business Unit, reports direct ownership of 3,000 Ordinary Shares. The position also includes 1,600 restricted stock units (RSUs), which are rights to receive one Ordinary Share each as they vest.
The RSUs vest in tranches of 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028. In addition, Miyabashira holds Tax Obligation Awards that are economically equivalent to Ordinary Shares and are designed to be settled in cash primarily to cover tax obligations at the then-current market price when they vest.
Takeda Pharmaceutical Co. Ltd. executive Gabriele Ricci, Chief Data & Tech. Officer, reports beneficial ownership of 124,132 American Depositary Shares. This includes 45,774 restricted stock units, each representing a contingent right to one ADS, vesting on July 1, 2026 (21,952), July 1, 2027 (16,012) and July 1, 2028 (7,810).
Takeda Pharmaceutical Co. Ltd. director Kimberly A. Reed filed an initial beneficial ownership report showing a mix of share holdings and equity awards. She reports direct holdings of 9,700 Ordinary Shares and 8,975 American Depositary Shares. The filing also lists several Tax Obligation Awards, each economically equivalent to one Ordinary Share, covering 1,152, 1,192 and 1,180 underlying Ordinary Shares with vesting and expiration dates on June 1 of 2026, 2027 and 2028. Footnotes explain that separate restricted stock unit awards will vest in tranches of 3,100, 3,400 and 3,200 Ordinary Shares on those same dates, with each RSU converting into one Ordinary Share and then into an equivalent number of American Depositary Shares following vest.
Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares. This amount represents an award of restricted stock units, each convertible into one ADS, subject to a multi-year vesting schedule.
The RSUs vest in three equal time-based tranches: 49,750 shares on July 1, 2026, 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. All shares are reported as directly owned, reflecting a significant equity-based compensation grant that aligns the executive’s interests with long-term company performance.